BOSTON, April 30, 2019 /PRNewswire/ — OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include:
The OM1 registries are continually enrolling and updating and include patient reported outcomes as well as linkage to other data sources. These specialized clinical databases are used for streamlining research, understanding treatments and improving patient outcomes for life sciences companies and providers.
“Understanding these conditions at a deeper level is critical to every stakeholder. We are proud to be advancing research and improving care through better, more complete and timely data,” said Dr. Richard Gliklich, CEO of OM1. “Enabling our customers to have direct access to research-grade data will help advance care even more rapidly.”
The registry data is available for licensing and through OM1’s advanced data visualization and analytics tools. For more information, visit www.om1.com.
Contact
Renee Hurley
Head of Marketing, OM1
617-620-9571
rhurley@om1.com
About OM1
OM1 is a leading health outcomes and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes. OM1’s real world evidence platform, clinical registries and AI technologies enable clients to accelerate research, measure and benchmark health outcomes and to personalize patient care.
View original content to download multimedia:http://www.prnewswire.com/news-releases/om1-expands-rheumatology-conditions-with-specialized-data-for-licensing-and-advanced-analytics-300840558.html
SOURCE OM1
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX)…
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…
12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…